RNTX Stock Forecast: Rein Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Rein Therapeutics, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 39 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Rein Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (72): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (15): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
RNTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RNTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 19 most recent actions, 1 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Nov 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 18 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 20 July 2026 | Maxim Group | Initiates | Buy | $4.00 |
| 1 June 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $8.00 |
| 21 Jan 2026 | Brookline Capital | Downgrade | Hold | — |
| 22 Sept 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 19 Aug 2025 | Brookline Capital | Downgrade | Hold | — |
| 18 Apr 2024 | Ladenburg Thalmann | Maintains | Buy | $9.00 → $19 |
| 1 Dec 2023 | Ladenburg Thalmann | Upgrade | Buy | $9.00 |
| 30 June 2022 | HC Wainwright & Co. | Maintains | Buy | $2.00 → $1.00 |
| 29 June 2022 | William Blair | Downgrade | Market Perform | — |
| 5 June 2020 | HC Wainwright & Co. | Maintains | Buy | $3.00 → $2.00 |
| 31 Mar 2020 | H.C. Wainwright | Maintains | Buy | — |
| 31 Mar 2020 | HC Wainwright & Co. | Maintains | Buy | $6.00 → $3.00 |
| 9 Apr 2019 | Canaccord Genuity | Maintains | Buy | $19 → $5.00 |
| 11 Mar 2019 | H.C. Wainwright | Initiates | Buy | — |
| 24 July 2017 | Bank of America | Initiates | Buy | — |
| 24 July 2017 | Canaccord Genuity | Initiates | Buy | — |
| 24 July 2017 | Jefferies | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RNTX.
This page is one stock. Monday covers all of them.
RNTX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
RNTX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Rein Therapeutics, Inc. returned −70.8% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
RNTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 3.9×
- EV / EBITDA
- —
Cheaper than 24% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −100.5%
- Return on assets
- −24.6%
- Dividend yield
- —
Higher than 13% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rein Therapeutics, Inc. has a market value of $31.7M and an enterprise value of $41.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$49.8M.
Free cash flow in the twelve months to 30 June 2026: −$18.8M.
Rein Therapeutics, Inc. employs 10 people.
Data provided by Twelve Data
RNTX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at RNTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Rein Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about RNTX
What is the RNTX stock price forecast for 2026-2027?
The median 12-month analyst price target for Rein Therapeutics, Inc. is $6, with estimates ranging from $4 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RNTX stock a buy right now?
Of the 2 analysts covering Rein Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rein Therapeutics, Inc. 39 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RNTX?
As at 21 Nov 2026, Rein Therapeutics, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (72 of 100).
Will RNTX stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $6, and Ticker Nerd's factor model ranks Rein Therapeutics, Inc. 39 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RNTX stock forecast for 2030?
No analyst covering Rein Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $8 over the next 12 months.
How has RNTX stock performed over the past year?
Rein Therapeutics, Inc. returned -70.8% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Rein Therapeutics, Inc. do?
Rein Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for orphan pulmonary and fibrosis indications. The company’s current pipeline centers on LTI-03, a peptide being advanced for idiopathic pulmonary fibrosis, and LTI-01, a therapy candidate for loculated pleural effusion.
About Rein Therapeutics, Inc.
Rein Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for orphan pulmonary and fibrosis indications. The company’s current pipeline centers on LTI-03, a peptide being advanced for idiopathic pulmonary fibrosis, and LTI-01, a therapy candidate for loculated pleural effusion. Its portfolio also includes additional preclinical programs targeting fibrosis-related pathways and cystic fibrosis. Rein Therapeutics develops peptide-based and protein-based therapeutics designed to address serious diseases with limited treatment options, making it a specialized player in respiratory and fibrotic medicine. Headquartered in Austin, Texas, Rein Therapeutics serves the biopharmaceutical market through research, clinical development, and product advancement for highly targeted rare-disease applications.
CEO Dr. James Brian Windsor Ph.D. · 10 employees · United States · https://www.reintx.com